Shield Therapeutics plc
("Shield" or the "Company")
2017 Annual Report and 2018 AGM Notice
London, UK, 5 June 2018. Shield Therapeutics plc (LSE:STX), announces that the following documents have been sent to shareholders:
• Annual Report and Accounts for the year ended 31 December 2017
• Notice of Annual General Meeting ("AGM") 2018
In accordance with the AIM Rule 26, these documents are available on Company's website at, https://www.shieldtherapeutics.com/investors/corporate-documents/.
The AGM is scheduled to be held at 2.00pm BST on Wednesday 27 June 2018 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London, EC2M 7SH.
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Karl Keegan, Chief Financial Officer
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a commercial stage pharmaceutical company, delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of all adults with iron deficiency with or without anaemia which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.
